Prudent Man Advisors LLC Increases Position in Eli Lilly and Company $LLY

Prudent Man Advisors LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 103.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,783 shares of the company’s stock after acquiring an additional 906 shares during the quarter. Eli Lilly and Company comprises about 0.7% of Prudent Man Advisors LLC’s portfolio, making the stock its 27th biggest position. Prudent Man Advisors LLC’s holdings in Eli Lilly and Company were worth $1,916,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Maryland Capital Advisors Inc. purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at $25,000. Miller Global Investments LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at $33,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after acquiring an additional 24 shares during the period. Dorato Capital Management purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at $36,000. Finally, New England Capital Financial Advisors LLC increased its holdings in shares of Eli Lilly and Company by 142.9% in the 4th quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LLY has been the topic of several research analyst reports. Daiwa Securities Group boosted their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. CICC Research boosted their target price on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 11th. Leerink Partners set a $1,119.00 target price on Eli Lilly and Company in a research note on Tuesday, May 26th. Bank of America boosted their target price on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Finally, Guggenheim restated a “buy” rating and set a $1,183.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,227.00.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark reversed its earlier exclusion and will now cover Eli Lilly’s Zepbound, a meaningful reimbursement win that could expand patient access and bolster obesity-drug sales. Article Title
• Positive Sentiment: WeightWatchers Med+ is now available through LillyDirect, reinforcing Lilly’s distribution ecosystem and strengthening its leadership in chronic weight management. Article Title
• Positive Sentiment: Lilly announced a new Phase 2b obesity trial for macupatide–eloralintide, adding another potential growth driver to its weight-loss pipeline beyond current GLP-1 products. Article Title
• Positive Sentiment: Jim Cramer highlighted Lilly as a potential winner against competitors, with attention on its new pill version of its weight-loss drug and broader competitive advantages. Article Title
• Positive Sentiment: Analysts and market commentary continue to frame LLY as a long-term winner, citing strong execution, deal-making, and diversification efforts beyond obesity drugs. Article Title
• Neutral Sentiment: Lilly also received coverage around its Phase 3 Libretto-432 cancer study and a $1.9 billion Ascidian partnership, both of which support the pipeline but are longer-term in nature. Article Title
• Neutral Sentiment: Broader health-care sector commentary and stock-screen articles were generally supportive, but they are less likely to be a direct driver of LLY’s move than the CVS and pipeline news. Article Title

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,133.15 on Monday. The stock has a market cap of $1.07 trillion, a P/E ratio of 40.25, a P/E/G ratio of 1.24 and a beta of 0.53. The stock has a 50-day moving average of $974.59 and a two-hundred day moving average of $1,012.96. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,166.29.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s payout ratio is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.